Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.
Convection-enhanced delivery (CED) is a recently developed technique for local delivery of agents to a large volume of tissue in the central nervous system (CNS). We have previously reported that this technique can be applied to CNS delivery of nanoparticles including viruses and liposomes. In this paper, we describe the impact of key physical and chemical properties of infused molecules on the extent of CED-mediated delivery. For simple infusates, CED distribution was significantly increased if the infusate was more hydrophilic or had less tissue affinity. Encapsulation of tissue-affinitive molecules by neutral liposomes significantly increased their tissue distribution. The poorer brain distribution observed with cationic liposomes, due to their greater tissue affinity, was completely overcome by PEGylation, which provides steric stabilization and reduced surface charge. Finally, liposomal encapsulation of doxorubicin reduced its tissue affinity and substantially increased its distribution within brain tumor tissue. Taken together, the physical and chemical properties of drugs, small molecules and macromolecular carriers determine the tissue affinity of the infusate and strongly affect the distribution of locally applied agents. Thus, an increased and more predictable tissue distribution can be achieved by reducing the tissue affinity of the infusate using appropriately engineered liposomes or other nanoparticles.
Saito
Ryuta
R
Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, Mission Center Building, 94103, USA.
Krauze
Michal T
MT
Noble
Charles O
CO
Tamas
Matyas
M
Drummond
Daryl C
DC
Kirpotin
Dimitri B
DB
Berger
Mitchel S
MS
Park
John W
JW
Bankiewicz
Krystof S
KS
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001921:Brain / Q000502:physiology*; D001932:Brain Neoplasms / Q000188:drug therapy; D002626:Chemistry, Pharmaceutical; D018481:Convection; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000295:instrumentation*; D004563:Electrochemistry; D005079:Excipients; D008081:Liposomes; D008297:Male; D049329:Nanostructures; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D014677:Pharmaceutical Vehicles; D011092:Polyethylene Glycols / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D005079:Excipients; D008081:Liposomes; D004364:Pharmaceutical Preparations; D014677:Pharmaceutical Vehicles; D011092:Polyethylene Glycols